Visionshopsters announcing a new report 'Disease and Therapy Review: Rheumatoid Arthritis'

Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format.

Online PR News – 15-January-2010 – – The Rheumatoid Arthritis Disease and Therapy Review provides an overview of the disease and related conditions, with incidence and prevalence numbers and percentages for major countries worldwide, and an overview of treatment. Dosing and treatment cost information is provided for various treatment types. General information on the rheumatoid arthritis market, as well as sales of leading drugs and therapies are provided.

Disease and Therapy Reviews were developed to provide a basic understanding of the key facts about a disease and market in a quick, easy-to-read format. These reports are prepared by the senior market research team of Timely Data Resources. Each Disease and Therapy Review provides a concise analysis of the most important information about a particular disease, its treatment, and the market opportunities. Reports begin with an overview of the condition, and also contain tables that summarize the available worldwide incidence and prevalence data for the condition, a review of current diagnosis strategies and treatment options, general information about the market size, and information about important market trends. The data contained in these reports comes from key industry secondary data sources, such as the Timely Data Resources Incidence and Prevalence Database, and Lange's Current Medical Diagnosis and Treatment. This information is supplemented by reviews of analyst reports, company reports, and medical websites. Sources and references are provided.

Table Of Contents :

I. Overview

II. Incidence and Prevalence
Incidence Table: (US, UK, France, Worldwide)
Prevalence Table: (US, UK, France, Germany, Italy, Spain, Japan, China, India, Mexico, Worldwide)

III. TREATMENT and Dosing
NSAIDs
Corticosteroids
Disease-modifying antirheumatic drugs (synthetic DMARDs)
Methotrexate (MTX)
Sulfasalazine
Leflunomide
Minocycline
Biologic DMARDs: Tumor necrosis factor (TNF) inhibitors

IV. DOSING

V. MARKET SIZE

VI. COMMENTS

VII. References/Resources

To know more about this report & to buy a copy please visit :
http://www.visionshopsters.com/product/816/Disease-and-Therapy-Review-Rheumatoid-Arthritis.html

Bookmarkse-mailGoogledel.icio.usStumbleUponSlashdotFurlDiggTechnoratiYahooMyWebBlinkListSpurlRawSugarWists
 
 
Contact Information